Drug Trial Radar · NCT06164704
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Participants With Chronic Rhinosinusitis With Nasal Polyps
Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
81
Actual
Start
Dec 18, 2023
Primary completion
Jul 7, 2025
Study completion Jul 22, 2025
Sponsor
- Lead sponsor
- Upstream Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 11, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to assess the safety and tolerability of verekitug (UPB-101) compared to placebo.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
Verekitug (UPB-101)Drug
Verekitug (UPB-101) 0.5 mL of formulated solution (100 mg verekitug \[UPB-101\])
PlaceboDrug
Verekitug (UPB-101) matching placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Nasal Polyp Score (NPS) at Week 24Time frame: Baseline, Week 24
Locations
41 sites in 5 countries. Site status is shown where the registry gives one.
Sensa Health LA (Sensa Health Clinical Research)
Los Angeles, California
Newport Native MD, Inc.
Newport Beach, California
DaVinci, Research LLC
Roseville, California
Senta Clinic
San Diego, California
University of Missouri
Columbus, Colorado
Western States Clinical Research, Inc.
Wheat Ridge, Colorado
Alfa Medical Research
Hollywood, Florida
Novaceut Clinical Research
Miami, Florida
Well Pharma Medical Research Corp.
Miami, Florida
IMIC Inc.
Miami, Florida
University of South Florida
Tampa, Florida
Treasure Valley Medical Research
Boise, Idaho
The University of Chicago
Chicago, Illinois
Advanced ENT and Allergy
Louisville, Kentucky
Chesapeake Clinical Research, Inc.
White Marsh, Maryland
Brigham and Women's Hospital
Boston, Massachusetts
Northwell Health/Division of Allergy and Immunology
Great Neck, New York
University of Cincinnati Medical Center
Cincinnati, Ohio
Allergy, Asthma & Clinical Research Center
Oklahoma City, Oklahoma
Spartanburg /Greer ENT & Allergy
Spartanburg, South Carolina
Orion Clinical Research
Austin, Texas
Alina Clinical Trials, LLC.
Dallas, Texas
Ears Nose and Throat Associates of Texas
McKinney, Texas
Alamo Ent Associates
San Antonio, Texas
Eastern Virginia Medical School
Norfolk, Virginia
Bellingham Asthma, Allergy & Immunology Clinic
Bellingham, Washington
Allergy, Asthma and Sinus Center, S.C.
Greenfield, Wisconsin
NZZ MUDr Pavel Navratil
Olomouc, Czech Republic, Czechia
Charite Universitaetsmedizin Berlin
Berlin, Germany
Universitaetsklinik Muenster, Klinik fur Hals-, Nasen- und Ohrenheilkunde
Münster, Germany
Universitätsklinik Tuebingen
Tübingen, Germany
Centrum Medyczne Angelius Provita
Katowice, Poland
Centrum Medyczne "All-Med" Badania Kliniczne spolka komandytowa
Krakow, Poland
Centrum Medyczne PROMED
Krakow, Poland
CENTRUM SŁUCHU I MOWY Sp. z o.o.
Nadarzyn, Poland
Centrum Medyczne Lucyna Andrzej Dymek s.c
Strzelce Opolskie, Poland
Centro Médico Teknon
Barcelona, Spain
Hospital Universitario de Jerez de la Frontera
Cadiz, Spain
Hospital Universitario Fundacion Jimenez Diaz (UAM-FJD) Consultas Externas Isaac Peral
Madrid, Spain
Hospital Universitario Ramón y Cajal
Madrid, Spain
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.